Abstract
Gastric arterial embolization has historically been used to treat gastrointestinal hemorrhage. After the discovery of the appetite-inducing hormone, ghrelin, gastric fundal embolization or bariatric embolization has gained importance for weight reduction. Although still in initial experimental stage, the only effective nonsurgical intervention for reduction of ghrelin is bariatric gastric embolization. Preliminary findings from early single-arm clinical trials have demonstrated that bariatric embolization results in significant decrease of plasma ghrelin levels and leads to weight loss. It is a safe, novel, promising technique that has the potential to be an alternative procedure to surgery for patients with body mass index between 30 and 40. Common side effects include transient epigastric pain, nausea, vomiting, and stomach ulcers.
Original language | English (US) |
---|---|
Title of host publication | Obesity and Diabetes |
Subtitle of host publication | Scientific Advances and Best Practice |
Publisher | Springer International Publishing |
Pages | 619-629 |
Number of pages | 11 |
ISBN (Electronic) | 9783030533700 |
ISBN (Print) | 9783030533694 |
DOIs | |
State | Published - Dec 14 2020 |
Keywords
- Appetite-stimulating hormone
- Bariatric embolization
- Ghrelin
- Left gastric artery embolization
- Weight loss
ASJC Scopus subject areas
- General Medicine
- General Biochemistry, Genetics and Molecular Biology